Sheng‐Shun Yang

National Chung Hsing University — Taiwan

Medicine · Health Sciences

35h-index6.0kcitations237works4.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatitis C virus research(118), Liver Disease Diagnosis and Treatment(101), Hepatitis B Virus Studies(83), Liver Disease and Transplantation(21), Hepatocellular Carcinoma Treatment and Prognosis(18)

Publications234 total

Effect of Glycated Hemoglobin Levels on Serum Mac‐2 Binding Protein Glycosylation Isomer in the Diagnosis of Hepatitis C‐Virus Related Hepatic Fibrosis
Journal of Medical Virology·2026Open Access
Correction: Construction of a prognostic model for colorectal cancer liver metastasis based on single-cell transcriptomics and regulation of the MIF pathway
Frontiers in Oncology·2025Open Access
Metabolic Syndrome and Metabolic Dysfunction-associated Steatotic Liver Disease in Fibromyalgia
Archives of Rheumatology·2025Open Access
Survival impact of hepatitis C virus eradication in patients with or without active hepatocellular carcinoma: A nationwide cohort study
European Journal of Cancer·2025
Predictive Value of Serum Mac‐2 Binding Protein Glycosylation Isomer for Hepatic Fibrosis in Hepatitis C Virus–Infected Patients With Metabolic Dysfunction–Associated Steatotic Liver Disease
Journal of Gastroenterology and Hepatology·2025· 1 cited
Construction of a prognostic model for colorectal cancer liver metastasis based on single-cell transcriptomics and regulation of the MIF pathway
Frontiers in Oncology·2025Open Access
Expert consensus on clinical usefulness of M2BPGi for managing chronic liver diseases
Journal of the Formosan Medical Association·2025· 1 citedOpen Access
Switching to tenofovir alafenamide in virally-suppressed chronic hepatitis B patients with renal/hepatic impairment: Phase 2 study sub-analysis from Taiwan
Journal of the Formosan Medical Association·2025Open Access
Immune-mediated adverse events in the randomized phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer
The Oncologist·2025· 1 citedOpen Access
Effects of Sofosbuvir/Velpatasvir Therapy on Extrahepatic Manifestations in Patients With Type 2 Diabetes and Chronic Hepatitis C: Insights From a Nationwide Hepatitis C Virus Registry in Taiwan
The Kaohsiung Journal of Medical Sciences·2025Open Access
Single-cell analyses unravel ecosystem dynamics and intercellular crosstalk during gallbladder cancer malignant transformation
Hepatology Communications·2025· 1 citedOpen Access
WED-272 Real-world efficacy and safety of universal 8-week Glecaprevir/ Pibrentasvir in CHC patients with early CKD or Pre-ESRD: insights from a nationwide HCV registry in Taiwan
Journal of Hepatology·2025
The Triglyceride-Glucose Index as a Biomarker for Insulin Resistance Following Hepatitis C Virus Eradication: A Prospective Cohort Study
Journal of Clinical Medicine·2025· 1 citedOpen Access
Risk factors of early dysfunction after switching from plastic to metal stents in malignant extrahepatic biliary obstruction
Journal of the Chinese Medical Association·2025· 1 citedOpen Access
Predicting Neoplastic Polyp in Patients With Gallbladder Polyps Using Interpretable Machine Learning Models: Retrospective Cohort Study
Cancer Medicine·2025· 2 citedOpen Access
Posttreatment FIB-4 score change predicts hepatocellular carcinoma in chronic hepatitis C patients: Findings from the Taiwan hepatitis C registry program
Journal of the Formosan Medical Association·2025· 3 citedOpen Access
Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection
Alimentary Pharmacology & Therapeutics·2025· 9 cited
Direct-acting antiviral therapy for patients with hepatitis C virus-related hepatocellular carcinoma: A nationwide cohort study
Clinical and Molecular Hepatology·2025· 6 citedOpen Access
Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trial
˜The œLancet. Gastroenterology & hepatology·2025· 18 cited
Real‐world efficacy and safety of universal 8‐week glecaprevir/pibrentasvir in patients with chronic hepatitis C with early chronic kidney disease or pre‐end‐stage renal disease: Insights from a nationwide hepatisis <scp>C virus</scp> registry in Taiwan
The Kaohsiung Journal of Medical Sciences·2025· 3 citedOpen Access
page 1 of 12Next →

Frequent Co-authors

Jia‐Horng Kao(20), Chun‐Jen Liu(19), Ding‐Shinn Chen(15), Chen‐Hua Liu(14), Wei‐Wen Su(11), Cheng‐Yuan Peng(11), Pei‐Jer Chen(10), Wan‐Long Chuang(9), Chih‐Lin Lin(9), Tung‐Hung Su(8), Tai‐Chung Tseng(8), Gin‐Ho Lo(7), Kuo‐Chih Tseng(7), Tsai‐Yuan Hsieh(7), Chi‐Sen Chang(7), Ming‐Lung Yu(7), Lein‐Ray Mo(6), Cheng‐Chao Liang(6), Chung‐Feng Huang(6), Chia‐Yen Dai(6)